CureVac NV (CVAC)

traders view logo Charts by TradingView

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

CureVac NV (CVAC) Profile

CureVac N.V., a clinical-stage biopharmaceutical firm, is focused on the development of a diverse range of revolutionary therapies based on messenger ribonucleic acid (mRNA). It is working to develop prophylactic vaccines, including CV7202, a prophylactic mRNA-based vaccine candidate against COVID-19; a vaccine for lassa yellow fever; a vaccine for the respiratory syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and immunisations against Rota, malaria, and universal influenza. Additionally, the company is developing RNA-based cancer immunotherapies, comprising ofCV8102 (BI 1361849), a self-adjuvanting mRNA vaccine in Phase 1 clinical trials for non-small cell lung cancer, and also tumour-associated antigens and shared neo-antigens. Additionally, the company is developing protein-based therapeutics for Cas9 gene editing, ophthalmic and respiratory illnesses, as well as therapeutic antibodies. The headquarters of the corporation are in T14 Bingen, Germany. Full Time Employees: 455 latest stock price29.860.00 (0.00%) At close: 04:00 PM as at 1/12/2022 EST. Market cap 5,585B USD. CureVac total assets for the quarter ending September 30, 2021, were $1.588B.

CureVac NV (CVAC.xnas) News
CureVac is developing CV2CoV, a preclinical second-generation mRNA vaccine potential, against SARS-CoV-2 in partnership with GlaxoSmithKline Plc (NYSE: GSK). In Q1 2022, the business plans to initiate a Phase 1 trial evaluating CV2CoV.

Holding cost
Trading hours in US Eastern Time
10:00 - 18:30
10:00 - 18:30
10:00 - 18:30
10:00 - 18:30
10:00 - 18:30

Share CFD Trading FAQ

Each investor owning shares of a company is also owning fragments of the company. A quite simple way to explain what a stock is is basically when a company divides itself into several shares and then it makes a part of these equities available to the public, at a price. Each investor owning shares of a company is owning fragments of the company.

While shares represent units of ownership within a company Contracts for Difference (CFDs) allow traders to speculate on the future share price fluctuations of an underlying asset. Thus when trading CFDs traders do not physically own the underlying asset. CFDs are available for a range of underlying assets, such as shares, commodities, and foreign exchange, and indices.

Why Trade CureVac NV (CVAC.xnas) with FP Markets? An Australian-regulated forex & CFD broker
go long or short
Go Long or Short

Increase your ability to profit in
all market conditions
Leverage options up to 20:1

direct market access
Direct Market Access (DMA) Execution

Real-time, transparent share prices
Control, Functionality and deep liquidity
Full Market depth & see your orders in the queue

advanced platforms
Advanced Platforms
& Technology

MT4, MT5, Webtrader & Iress with
superior client portal

24/5 Multilingual customer support
24/5 Multilingual
Customer Support

Award winning support &
personal account managers

global exposure
Global Exposure

Low margins and competitive commission
+10,000 products on global stocks
across 4 continents

earn dividends
Earn Dividends

On long positions
No ownership of physical
shares necessary

Bắt Đầu Giao Dịch sau một vài phút

bullet Truy cập trên 10.000 công cụ tài chính
bullet Tự động mở & đóng vị thế
bullet Lịch sự kiện tin tức & kinh tế
bullet Chỉ báo & biểu đồ kỹ thuật
bullet Bao gồm nhiều công cụ hơn

Bằng việc cung cấp email của mình, bạn đồng ý với chính sách về quyền riêng tư của FP Markets và nhận các tài liệu marketing trong tương lai từ FP Markets. Bạn có thể hủy đăng ký bất cứ lúc nào.

Source - cache | Page ID - 16923

Get instant Updates in Telegram